US 12,227,559 B2
Collagen-localized immunomodulatory molecules and methods thereof
Karl Dane Wittrup, Boston, MA (US); Noor Momin, Cambridge, MA (US); Joseph Palmeri, Cambridge, MA (US); and Magnolia Chinn, Cambridge, MA (US)
Assigned to MASSACHUSETTS INSTITUTE OF TECHNOLOGY, Cambridge, MA (US)
Filed by MASSACHUSETTS INSTITUTE OF TECHNOLOGY, Cambridge, MA (US)
Filed on Nov. 18, 2022, as Appl. No. 18/056,825.
Application 18/056,825 is a continuation of application No. 16/523,965, filed on Jul. 26, 2019, abandoned.
Claims priority of provisional application 62/738,981, filed on Sep. 28, 2018.
Prior Publication US 2023/0174623 A1, Jun. 8, 2023
Int. Cl. A61K 39/00 (2006.01); C07K 14/00 (2006.01); C07K 14/47 (2006.01); C07K 14/705 (2006.01); C07K 14/715 (2006.01); C07K 14/725 (2006.01); C07K 14/78 (2006.01); C12N 5/0783 (2010.01); A61K 38/00 (2006.01)
CPC C07K 14/78 (2013.01) [A61K 39/0011 (2013.01); A61K 39/4611 (2023.05); A61K 39/4631 (2023.05); A61K 39/4636 (2023.05); A61K 39/464499 (2023.05); C07K 14/473 (2013.01); C07K 14/4741 (2013.01); C07K 14/7051 (2013.01); C07K 14/70521 (2013.01); C07K 14/70532 (2013.01); C07K 14/7155 (2013.01); C12N 5/0636 (2013.01); A61K 38/00 (2013.01); A61K 2239/31 (2023.05); A61K 2239/38 (2023.05); A61K 2239/57 (2023.05); C07K 2317/92 (2013.01); C07K 2319/03 (2013.01); C07K 2319/30 (2013.01); C07K 2319/74 (2013.01)] 10 Claims
 
1. An immunomodulatory fusion protein comprising:
(i) an immunomodulatory domain comprising IL-2;
(ii) a collagen-binding domain comprising LAIR 1 having the amino acid sequence of SEQ ID NO: 98; and
(iii) an albumin linker,
wherein the immunomodulatory domain is operably linked with the linker to the collagen-binding domain;
wherein the fusion protein binds type I and/or type IV collagen upon administration in vivo and the collagen-binding domain increases tumor retention and prevents systemic exposure to the cytokine.